Cannabinoid Market Snapshot: GW's Epilepsy Success Bodes Well
• By Emily Hayes
Over 50 cannabinoid drugs are in development, most commonly targeting central nervous system diseases. Analysts think the relaxation of restrictions on medical cannabis is helping with perception problems, but so far there’s little evidence the market isn’t just smoke and mirrors.
The market for pharmaceutical-grade cannabinoid drugs is looking brighter following the success of GW Pharmaceuticals PLC in a third pivotal trial in hard-to-treat forms of epilepsy.
UK-based GW Pharmaceuticals recently announced that its cannabinoid Epidiolex – which includes cannabidiol (CBD) but not the psychoactive tetrahydrocannabinol (THC)...
Apogee Therapeutics reports data from Phase II APEX trial of its long-acting antibody against atopic dermatitis, showing similar efficacy to Regeneron/Sanofi’s Dupixent and Eli Lilly’s Ebglyss.
The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.
Apogee Therapeutics reports data from Phase II APEX trial of its long-acting antibody against atopic dermatitis, showing similar efficacy to Regeneron/Sanofi’s Dupixent and Eli Lilly’s Ebglyss.
Public Company Edition: A breakthrough designation, data and deals prompted big follow-on public offerings in late June and early July, including $402.5m for Cidara, $250.8m for Kymera and $230m for Dyne. Also, Revolution Medicines accessed up to $2bn from Royalty Pharma.